Cellix Bio innovative platform
an effective methodology to drug design that focuses on creating new molecular entities with improved pharmacokinetic profile and synergistic pharmacology. Synergix aims to target known biomolecular pathophysiological pathways considered likely to yield significant therapeutic benefits and to develop structural molecular chemistries to optimize the Company’s New Molecular Entities (NMEs).
The NMEs are are designed to be cleaved by specific enzymes exclusively within cells or by the mediation of specific intestinal enzymes. This cleavage potentially releases two bioactives independently, which in turn would allow the bioactives to reach their targets more efficiently, with greater efficacy and better PK-PD profile than if the bioactives were dosed independently or in combination.
We selected established drugs and transform them utilizing long chain fatty acid chemistry to enhance their molecular profile and augment their pharmacological and disease modifying potential.